|
GLE1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.27269999988999E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.17050000003616E-06 |
| Normal-vs-Stage2 |
3.189400E-04 |
| Normal-vs-Stage3 |
2.48549999470882E-08 |
| Normal-vs-Stage4 |
5.28750000450273E-08 |
| Stage1-vs-Stage2 |
8.900200E-01 |
| Stage1-vs-Stage3 |
8.313700E-02 |
| Stage1-vs-Stage4 |
7.616100E-02 |
| Stage2-vs-Stage3 |
3.165800E-01 |
| Stage2-vs-Stage4 |
2.208800E-01 |
| Stage3-vs-Stage4 |
6.788400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.98950000310327E-08 |
| Normal-vs-AfricanAmerican |
5.858200E-03 |
| Normal-vs-Asian |
2.17429999999075E-05 |
| Caucasian-vs-AfricanAmerican |
4.847000E-01 |
| Caucasian-vs-Asian |
7.890800E-01 |
| AfricanAmerican-vs-Asian |
6.480200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.38919999947973E-08 |
| Normal-vs-Female |
2.92359999987113E-07 |
| Male-vs-Female |
1.330420E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.33739999999649E-05 |
| Normal-vs-Age(41-60Yrs) |
5.72799999987161E-07 |
| Normal-vs-Age(61-80Yrs) |
3.20180004731441E-09 |
| Normal-vs-Age(81-100Yrs) |
1.51304999999047E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.149200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.888380E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.299750E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.336820E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.268000E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.037500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.516220E-01 |
| Classical-VS-Follicular |
3.416400E-01 |
| Classical-VS-Other |
5.309600E-01 |
| Classical-VS-Normal |
4.58050000040622E-07 |
| Tall-VS-Follicular |
5.389200E-01 |
| Tall-VS-Other |
9.178800E-01 |
| Tall-VS-Normal |
4.23510000002736E-06 |
| Follicular-VS-Other |
8.459200E-01 |
| Follicular-VS-Normal |
3.37890000001728E-06 |
| Other-VS-Normal |
1.260010E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.13530000032259E-07 |
| Normal-vs-N1 |
5.06149999690564E-09 |
| N0-vs-N1 |
2.905600E-02 |
|
|
